Germany's Merck sells rights to Kuvan back to BioMarin Pharma

FRANKFURT (Reuters) - Germany's Merck KGaA said it agreed to return to BioMarin Pharmaceutical Inc the rights to the Kuvan drug against rare genetic disorder PKU as it seeks to focus on cancer,...